PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[wgg2]

Spideyboy, Can you answer a couple of questions?
Background: We know the balance study is compared to fabrazyme; and the bridge study is compared to replagal. Also, galafold, the newest treatment, treats FD with a GLA gene variant; about 40% of FD patients.
Questions: Is galafold a replacement for either of the above ERTs or prescribed in conjunction with them? Second, do we know whether PRX-102 also treats patients with the gene variant needed for the galafold treatment; thus potentially replacing it as a treatment? Thanks for your time and knowledge.